Form 4: Jasper Therapeutics Director Receives Automatic Stock Option Grant

Judith Anne Shizuru, a Director at Jasper Therapeutics, Inc., was granted options to purchase 7,500 shares of common stock at an exercise price of $6.77 per share, effective July 3, 2025, as part of the company's non-employee director compensation policy.

Summary

• Judith Anne Shizuru, a Director of Jasper Therapeutics, Inc. (JSPR), acquired 7,500 stock options.
• The options have an exercise price of $6.77 per share.
• The transaction occurred on July 3, 2025.
• The options become exercisable on July 3, 2026, and expire on July 3, 2035.
• The grant was automatic, in accordance with the Issuer's Non-Employee Director Compensation Policy, which grants 7,500 options to non-employee directors on the date of each annual meeting of stockholders.
• Following this transaction, Judith Anne Shizuru beneficially owns 7,500 derivative securities directly.

Sentiment

Score: 6

Explanation: The document reports a routine, expected compensation event for a director, which is a neutral to slightly positive indicator of consistent corporate governance and alignment of interests, without any significant new financial or operational information.

Positives

• The grant of stock options aligns with the company's established Non-Employee Director Compensation Policy, indicating consistent corporate governance practices.
• Providing equity compensation to directors helps align their interests with those of shareholders.

Future Outlook

No forward-looking statements or guidance are provided beyond the exercisability and expiration dates of the granted options.

Industry Context

This Form 4 filing reflects a standard practice of providing equity-based compensation to non-employee directors, common across many publicly traded companies in the biotechnology and pharmaceutical sectors, including Jasper Therapeutics. Such compensation aims to align director incentives with long-term shareholder value.

Comparison to Industry Standards

• The practice of granting stock options to non-employee directors is a common compensation strategy across various industries, including biotechnology, aligning director interests with company performance.
• The specific grant of 7,500 shares is within the typical range for director compensation at companies of similar market capitalization and stage of development, though exact figures vary widely based on company size, industry, and specific compensation policies.
• The exercise price of $6.77 per share, likely based on the market price at the time of grant, is standard for such option grants.

Corporate Governance

Related Party Transactions

• The grant of stock options to a director, Judith Anne Shizuru, constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholders by incentivizing long-term stock performance. It also represents a potential future dilution if options are exercised, though this is a standard part of equity compensation plans.
• Directors: The grant provides compensation and an incentive for continued service and performance.

Next Steps

• The options will become exercisable on July 3, 2026.
• The options will expire on July 3, 2035.

Key Dates

Keywords

Jasper Therapeutics, JSPR, SEC Form 4, Stock Option Grant, Insider Transaction, Director Compensation, Equity Compensation, Beneficial Ownership